Charité Research Organisation Holds Clinical Trial Cooperation Talks With Uzbekistan as BioPharma City Cluster Develops

• Charité Research Organisation, the German CRO affiliated with Charité — Universitätsmedizin Berlin, has held discussions with Uzbekistan’s Agency for the Development of the Medical and Pharmaceutical Industry covering prospects for cooperation in clinical research, trial infrastructure development, international partnerships, and specialist training.

• The meeting focused on Uzbekistan’s pharmaceutical sector reform agenda and the emerging BioPharma City pharmaceutical cluster — which includes GMP and GLP-compliant research centres and vivarium infrastructure — as a potential base for internationally aligned clinical trial activity.

Charité Research Organisation, the Berlin-based CRO operating within the Charité — Universitätsmedizin Berlin academic medical center network, held an online meeting with Uzbekistan’s Agency for the Development of the Medical and Pharmaceutical Industry on August 8, 2026, to discuss prospects for cooperation in clinical research and CRO infrastructure development. The meeting was held between Agency Director Abdulla Azizov and Charité Research Organisation Chief Executive Officer Frank Wagner, and was reported by the Agency on August 10, 2026.

The discussions covered four areas: developing clinical research in Uzbekistan in line with international standards, improving the country’s infrastructure for clinical trials, expanding international CRO cooperation, and enhancing the qualifications of Uzbek clinical research specialists. Uzbek representatives briefed the Charité Research Organisation delegation on ongoing pharmaceutical sector reforms, the legal and institutional framework being established for clinical research in the country, and the investment and research opportunities offered by the BioPharma City pharmaceutical cluster currently under development.

The BioPharma City cluster was presented as a core enabler of Uzbekistan’s clinical trial ambitions. The cluster includes modern research centers with GMP and GLP-compliant infrastructure and vivarium facilities designed to support both preclinical and clinical research operations to international standards — a prerequisite for attracting recognized international CRO partners and enabling clinical data generated in Uzbekistan to be accepted in regulatory submissions to agencies including the FDA and EMA. The sides also discussed opportunities for foreign investors and research organizations within the cluster’s development framework.

For the CRO sector, the meeting reflects a broader pattern of international CRO organizations exploring emerging Central Asian markets as part of geographic diversification strategies. Uzbekistan, with a population of over 37 million and an actively reforming pharmaceutical regulatory environment, represents an early-stage but strategically relevant new clinical trial geography — particularly for sponsors seeking patient population diversity and cost efficiency in Phase II and Phase III programs across infectious disease, metabolic disorders, and other high-prevalence indications in the region.

“The sides discussed developing clinical research in Uzbekistan in line with international standards, improving infrastructure for clinical trials, expanding international cooperation and enhancing the qualifications of specialists.”

The Agency for the Development of the Medical and Pharmaceutical Industry of Uzbekistan